吡格列酮膀胱癌

Pioglitazone bladder cancer

以上为机器翻译结果，快速获取精准的人工翻译结果，建议选择有道人工翻译

1
这些早期的结果显示吡格列酮应用与膀胱癌风险之间没有总体的联系。
These early results showed no overall association between Actos exposure and risk of bladder cancer.
2
这个时候，FDA的审核即将开始。该机构还没有得出结论说吡格列酮增加膀胱癌风险。
At this time, the FDA's review is ongoing. The agency has not concluded that Actos increases the risk of bladder cancer.
3
然后，就在几个月前，FDA就吡格列酮可能的膀胱癌发出警告；
Then, just several months ago, the FDA put out warning about possible bladder cancer with pioglitazone;

点击反馈